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in any medium, provided the original work is properly citeAlthough specialized pro-resolving mediators (SPMs) biosynthesized from poly-
unsaturated fatty acids are critical for the resolution of acute inflammation, the
molecules and pathways that induce their production remain elusive. Here, we
show that TLR7, a receptor recognizing viral ssRNA and damaged self-RNA,
mobilizes the docosahexaenoic acid (DHA)-derived biosynthetic pathways that
lead to the generation of D-series SPMs. In mouse macrophages and human
monocytes, TLR7 activation triggered production of DHA-derived monohydroxy
metabolome markers and generation of protectin D1 (PD1) and resolvin D1
(RvD1). In mouse allergic airway inflammation, TLR7 activation enhanced pro-
duction of DHA-derived SPMs including PD1 and accelerated the catabasis of
Th2-mediated inflammation. D-series SPMs were critical for TLR7-mediated
resolution of airway inflammation as this effect was lost in Alox15/ mice,
while resolution was enhanced after local administration of PD1 or RvD1.
Together, our findings reveal a new previously unsuspected role of TLR7
in the generation of D-series SPMs and the resolution of allergic airway inflam-
mation. They also identify TLR stimulation as a new approach to drive SPMs and
resolution of inflammatory diseases.INTRODUCTION
Prolonged or non-resolving inflammation underlies the patho-
genesis of a wide range of virtually unrelated diseases ranging
from autoimmune, metabolic and neurological disorders togy and Transplanta-
thens, Athens, Greece
ain Medicine, Center
ry, Harvard Institutes
nd Harvard Medical
enter for Basic Re-
of Athens, Athens,
þ30 210 6597545;
Ltd on behalf of EMBO. This
C BY 3.0), which permits u
d.allergies (Medzhitov, 2008; Nathan & Ding, 2010). Despite that,
mechanisms that control resolution of inflammation are not well
understood, mainly because resolution was envisaged for a long
time to occur passively following the decline of pro-inflamma-
tory responses. However, this paradigm has recently changed. It
has become apparent that resolution or catabasis (Bannenberg
et al, 2005) of inflammation is an active and tightly regulated
process that brings about the catabolism of pro-inflammatory
mediators, the removal of inflammatory cells and the restitution
of the tissue in a timely and highly coordinated manner (Nathan
& Ding, 2010; Serhan et al, 2007). This is critically dependent on
the activation of biochemical programs involving oxygenated
lipids derived from polyunsaturated fatty acids, altogether
termed specialized pro-resolving lipid mediators (SPMs) (Gilroy
et al, 2004; Serhan et al, 2008). SPMs are biosynthesized in
inflammatory exudates via the consecutive actions of lipoxy-
genase (ALOX-5, ALOX-12 and ALOX-15) and/or cyclo-
oxygenase (COX-2) enzymes and include protectins and D-seriesis an open access article under
se, distribution and reproduction
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Ourania Koltsida et al.resolvins derived from the omega-3 (v-3) fatty acid docosahex-
aenoic acid (DHA), E-series resolvins derived from eicosa-
pentanoic acid (EPA), and lipoxins derived from omega-6 fatty
acids (Serhan et al, 2008). Of interest, enzymes that are essential
for the production of SPMs such as COX-2 and ALOX-5 are also
the targets of major non-steroidal anti-inflammatory drugs (e.g.
ibuprofen, naproxen, celecoxib) or anti-leukotriene treatments
(e.g. zileuton), raising the possibility that certain widely used
anti-inflammatory drugs may actually inhibit/delay resolution
of inflammation despite their potent anti-inflammatory effects
(Bhavsar et al, 2010; Serhan et al, 2008).
Allergic asthma is a chronic inflammatory disease of the
airways characterized by Th2-mediated immune responses to
common aeroallergens in genetically susceptible individuals
(Holgate & Polosa, 2008; Kim et al, 2010). Th2 responses most
frequently develop early in life, persist even during asympto-
matic periods and are exacerbated in response to an environ-
mental trigger such as allergen exposure, viral infection or other
irritants leading to recurrent episodes of wheezing, breath-
lessness and coughing (altogether described as an asthmatic
attack), and eventually the progressive decline of lung function.
Although the intensity and duration of Th2 exacerbations
determine the severity of the asthmatic attack (Bousquet et al,
2000; Jackson et al, 2011; Locksley, 2010), the molecular
mechanisms and pathways controlling persistence or resolution
of Th2 allergic responses in the airways are largely unknown,
while therapies that actively resolve aberrant immune responses
in asthma have yet to be identified.
Multiple factors are proposed to influence the development or
persistence of inflammation in allergic asthma. Among them,
Toll-like receptors (TLRs) have taken centre stage by virtue of
their ability to recognize common allergens, microbial struc-
tures and endogenous ‘danger’ signals, and promote pro-
inflammatory responses in the airways (Edwards et al, 2012;
Palm et al, 2012). For instance, TLR4 senses house dust mite and
ragweed pollen (Hammad et al, 2009; Li et al, 2011; Trompette
et al, 2009), possibly through molecular mimicry, while TLR3
senses viral double stranded RNA, and both contribute to the
initiation or exacerbation of inflammation (Jeon et al, 2007;
Reuter et al, 2012; Torres et al, 2010). However, not all TLRs are
detrimental. TLR7 and TLR8 that recognize single stranded RNA
of respiratory viruses, and TLR9 that recognizes unmethylated
CpG islands of viral or bacterial DNA, exhibit surprising
immunoregulatory/immunomodulatory activity (Hennessy
et al, 2010; Kanzler et al, 2007). In mouse models of allergic
airway disease, prophylactic administration of TLR7/8 and
TLR9 agonists prevents the development of airway inflamma-
tion and hyperresponsiveness, through mechanisms that extend
beyond the modulation of the Th1/Th2 cytokine balance
(Fonseca & Kline, 2009; Moisan et al, 2006; Quarcoo et al,
2004; Sel et al, 2007; Xirakia et al, 2010). Moreover, in proof-of-
concept clinical trials in humans, treatment with TLR7, TLR8 or
TLR9 agonists reduces symptoms of allergic diseases such as
asthma (Cytos Biotechnology AG. Placebo-controlled phase II
study shows CYT003-QbG10 is safe and efficacious for the
treatment of allergic asthma. http://www.cytos.ch/?id=1572),
rhinitis (Horak, 2011) or rhinoconjunctivitis (Klimek et al,EMBO Mol Med (2013) 5, 762–775 2011), yet the mechanistic basis for these effects is lacking.
In this study, we used an established mouse model of acute
allergic airway inflammation, relevant to human allergic
asthma, to address the role of TLR7 in the resolution of
inflammation and identify specific SPM networks involved.RESULTS
Spatiotemporal resolution of allergic airway inflammation in
mice after discontinuation of allergen challenge
Although mouse models of asthma based on ovalbumin (OVA)
sensitization and challenge are widely used to study immuno-
inflammatory disease mechanisms, little information exists
about the spatiotemporal resolution of inflammation after
discontinuation of OVA challenge. We therefore monitored
the kinetics of resolution of various inflammatory and disease-
related parameters in a systematic manner (Fig 1A). Upon three
consecutive OVA challenges, OVA sensitized mice developed a
strong eosinophilic inflammation in the airways that was absent
from PBS challenged mice or healthy controls (Fig 1B).
Inflammation peaked at day 1 post-challenge and declined to
almost homeostatic levels by Day 10. Total cell counts in
bronchoalveolar lavage fluid (BALF) decreased by 36% by Day
4, 75% by day 7 and >90% by day 10 to levels that were not
statistically different to healthy controls (Fig 1C). These kinetics
were closely followed by eosinophils (34% by Day 4, 83% by
day 7 and >90% by Day 10) which also constitute the main
infiltrating cells in the BALF. In contrast, neutrophil numbers
decreased by 80% by day 4 and 100% by Day 7, lymphocytes by
32% by day 7 and 57% by day 10 (Fig 1C). At the tissue level,
inflammatory cell infiltrates peaked at day 1 post-challenge and
cleared with somewhat slower kinetics than total BALF cells
(Fig 1D) as did goblet cell metaplasia, a consequence of allergic
airway inflammation. Thus, although inflammatory cell infil-
trates and goblet cells in the lung gradually declined, they
remained at significant levels even at day 10 post-challenge
(Fig 1E). On the contrary, airway hyper-responsiveness, another
consequence of allergic airway inflammation and the cardinal
feature of human asthma, was detectable at day 1 post-
challenge, as indicated by the much lower effective dose of
methacholine (MCh) required to increase mean lung resistance
200% from baseline (ED200), but not at day 4 post-challenge or
thereafter (Fig 1F and Supporting Information Fig S1). Finally,
OVA-specific Th2 cell responses peaked at day 1 post-challenge
and gradually regressed to pre-challenge levels by day 10
(Fig 1G). Thus, despite some temporal differences in the
resolution of distinct inflammatory parameters, overall inflam-
mation peaks at day 1 post-challenge and gradually declines
thereafter. This makes this model a potent setup for studying
resolution of an acute allergic inflammatory response.
TLR7 regulates resolution of allergic airway inflammation in mice
Using this model, we next evaluated the hypothesis that TLR7
modulates resolution of allergic airway inflammation (Fig 2A).
Surprisingly, we found that Tlr7/mice exhibited significantly
delayed resolution of inflammation. At day 4 post-challenge,2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 763
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Figure 1. Spatiotemporal analysis of resolution of allergic airway inflammation post-OVA challenge.
A. Protocol of induction and time-course of resolution of allergic airway inflammation post-allergen challenge in wild-type mice.
B. Total cell counts in the BALF of PBS sensitized and challenged (PBS/PBS, n¼ 10), OVA sensitized and PBS challenged (OVA/PBS, n¼10) or OVA sensitized and
challenged (OVA/OVA, n¼ 30)mice at day 1 post-challenge. Results are expressed asmean SEM of 10–30mice per group from four independent experiments.
C. Total and differential cell counts in the BALF of OVA sensitized and challenged mice (OVA/OVA) at Days 1, 4, 7 and 10 post-allergen challenge expressed as
mean SEM of 30 mice per group from four independent experiments. Red dotted lines: cell counts of healthy (unchallenged) controls.
D. Histological assessment of lung inflammation of OVA sensitized and challenged (OVA/OVA) mice at Days 1, 4, 7 and 10 post-allergen challenge. Haematoxylin
and eosin (H&E)-stained lung sections and histological scoring expressed as mean values SEM of 10 mice/group from two independent experiments are
shown.
E. Histological assessment of mucus secretion of OVA sensitized and challenged (OVA/OVA) mice at Days 1, 4, 7 and 10 post-allergen challenge. Morphometric
analysis of Periodic acid Schiff (PAS)-stained sections expressed as mean values SEM of 10 mice/group from two independent experiments are shown.
F. Airway hyperesponsiveness of mice before (pre-challenge) and at days 1 and 4 post-challenge. LogED200, the effective dose of MCh required to increase mean
lung resistance by 200% from baseline, is shown. Values represent the mean SEM of seven mice per group. One representative from two independent
experiments.
G. Allergen-specific effector T cell responses in mediastinal LN cultures of OVA sensitized and challenged (OVA/OVA) mice at Day 1, 4, 7 and 10 post-allergen
challenge. Cytokine levels are expressed as mean values SEM in supernatants of OVA-stimulated mediastinal LN cultures of 10 mice per group from two
independent experiments. p< 0.05, p< 0.01, p<0.001, ns: non-significant compared to vehicle-treated control.
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Figure 2. TLR7 promotes resolution of allergic airway inflammation in mice.
A. Protocol of R-848 (200mg/mouse) treatment in wild-type mice, and comparison of resolution in wild-type and Tlr7/ mice.
B. Total cell counts in the BALF of OVA sensitized and challenged (OVA/OVA) wild-type (n¼30), R-848-treated (n¼30) and Tlr7/ (n¼20) mice at Days 1, 4, 7
and 10 post-challenge expressed as mean SEM of 20–30 mice per group.
C. Differential cell counts in BALF of wild-type (n¼ 30), R-848-treated (n¼ 30) and Tlr7/ (n¼ 20) mice at day 4 post-challenge expressed asmean SEM of 20–
30 mice per group are shown.
D. Histological assessment of lung inflammation of wild-type (n¼18), R-848-treated (n¼ 18) and Tlr7/ (n¼10) mice at day 4 post-challenge. Haematoxylin
and eosin (H&E)-stained lung sections and histological scoring expressed as mean values SEM from 10 to 18 mice/group are shown.
E. Histological assessment of mucus secretion of wild-type (n¼18), R-848-treated (n¼18) and Tlr7/ (n¼10) mice at day 4 post-challenge. Periodic acid Schiff
(PAS)-stained sections and morphometric analysis expressed as mean values SEM from 10 to 18 mice/group are shown.
F. Allergen-specific effector T cell responses in mediastinal LN cultures of OVA/OVA wild-type (n¼ 18), R-848-treated (n¼18) and Tlr7/ (n¼10) mice at day 4
post-challenge. Cytokine levels are expressed as mean values SEM in supernatants of OVA-stimulated mediastinal LN cultures of 10–18 mice per group.
p< 0.05, p< 0.01, p<0.001, ns: non-significant compared to vehicle (PBS)-treated control.
EMBO Mol Med (2013) 5, 762–775  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 765
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Figure 3. R-848 stimulates production of SPMs in murine allergic airway inflammation. OVA sensitized and challenged mice treated with 200mg R-848 or
vehicle control (PBS) on day 1 post-challenge were sacrificed at target time points and lungs analyzed.
A. LC-MS–MS chromatogram of Protectin D1 (PD1) identified in R-848-treated mouse lung.
B. Time-course of PD1 production during murine allergic airway inflammation. Black bars indicate baseline levels before administration of R-848. Blue bars
indicate vehicle (PBS). Red bars indicate treatment with R-848. p<0.05; Xp<0.05 compared to 0.
766total inflammatory cells and eosinophils in the BALF of Tlr7/
mice were 31 and 48% higher than in wild-type controls,
respectively (Fig 2B and C). This was associated with increased
inflammatory cell infiltrates in the lung, more pronounced
goblet cell metaplasia in the airways and higher Th2 cell
responses in lung-draining lymph nodes (Fig 2D–F). In contrast,
wild-type mice treated with R-848, a specific TLR7 agonist in
mice, exhibited accelerated resolution of allergic airway
inflammation. R-848 treatment reduced the number of inflam-
matory cells and eosinophils in the BALF by 37 and 35%,
respectively (Fig 2B and C), decreased the presence of
inflammatory cell infiltrates and goblet cells in the lung
(Fig 2D and E), and down-regulated allergen-specific Th2
responses in lung-draining lymph nodes (Fig 2F). These effects
were completely abrogated when R-848 was administered to
Tlr7/ mice (Supporting Information Fig S2), indicating the
specificity of the response. Examination of the resolution
interval (Ri; defined as the time required for cell numbers to
reach 50% of the numbers observed at the peak of inflammation
(Bannenberg et al, 2005)) of total inflammatory cells in the BALF
revealed a shift from 4.9 days for wild-type mice to 2.9 days
for R-848-treated mice and 6.1 days for Tlr7/ mice (Fig 2B).
Taken together, these results suggest that TLR7 activation
promotes resolution of inflammation in experimental asthma.
TLR7 activation drives the production of DHA-derived SPMs in
the lung
In view of the potent pro-resolving effects of TLR7 activation in
murine allergic airway inflammation, we compared the
lipidomic profiles of lungs from OVA challenged mice treated 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.with vehicle or R-848 using novel liquid chromatography-
tandem mass spectroscopy mediator lipidomics (LC-MS/MS)
(Yang et al, 2011). We identified the production of mono-
hydroxy biomarkers from the DHA, arachidonic acid (AA), and
EPA metabolomes, and the generation of AA-derived prosta-
glandins and leukotrienes (see Supporting Information Table S1
and Fig S3). These were increased in OVA challenged mice at
day 1 post-challenge compared to unchallenged (non-inflamed)
controls, and exhibited a variable course during the resolution of
airway inflammation. Of particular interest, we identified
protectin D1 (PD1/NPD1), a downstream bioactive product
from DHA and a potent pro-resolving lipid mediator, present at
all time points examined. PD1/NPD1 production was gradually
increased in resolving inflammation, and only declined at day 10
post-challenge once inflammation had resolved (Fig 3A and B).
We also identified both 17-hydroxydocosahexaenoic acid
(17-HDHA) and 14-hydroxydocosahexaenoic acid (14-HDHA),
biosynthetic pathways markers for PD1 and maresin 1. These
were elevated at the peak of the inflammatory response and
increased further as resolution progressed before declining at
day 10 (Supporting Information Table S1). Notably, PD1 levels,
as well as 17-HDHA and 14-HDHA, were rapidly up-regulated
upon R-848 treatment, suggesting that conversion of endogen-
ous DHA to its bioactive products may be central to TLR7-
mediated resolution of airway inflammation.
TLR7 activation initiates SPM biosynthesis in mouse and
human cells
Circulating substrates, polyunsaturated fatty acids DHA and
EPA and their flux into inflammatorymilieu is a known essentialEMBO Mol Med (2013) 5, 762–775
www.embomolmed.org Research Article
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Figure 4. R-848 stimulates production of SPMs and their precursors from deuterium-labelled DHA in monocytes and macrophages.
A. LC-MS-MS chromatograms of d5-7-HDHA, d5-14-HDHA and d5-17-HDHA produced by untreated (solid blue line) and R-848-treated (dashed red line) mouse
macrophages.
B,C. Increases inmousemacrophage d5-RvD1 and d5-PD1: quantitation (left) and LC-MS-MS identification (right) by R-848-treatedmousemacrophages. Results
are expressed as mean SEM of n¼4 for d5-RvD1 and n¼ 3 for d5-PD1.
D. Increase in human monocyte d5-PD1: quantitation (left) and LC-MS–MS identification (right) by R848-treated humanmonocytes. Results are representative
of n¼ 3. Proresolving lipid mediators were identified according to published criteria (Yang et al, 2011). p<0.05; Xp< 0.05 compared to 0; #p<0.05
compared to 1.source of SPMs biosynthesis and as a result, an important step in
resolution of inflammation (Kasuga et al, 2008). To determine
whether TLR7 (TLR7/8 in humans) activation directly induces
the production of SPMs, we used d5-containing DHA and
tracked deuterium incorporation into SPM profiles biosynthe-
sized by mouse and human cells using systematic LC-MS/MS-
based mediator lipidomics. We found significant increases in
7-hydroxydocosahexaenoic acid (d5-7-HDHA), d5-14-HDHA and
d5-17-HDHA (Fig 4A) as well as in SPMs d5-Resolvin D1 (RvD1;
Fig 4B) production by R-848-treated mouse macrophages when
compared to cells exposed to vehicle alone. PD1 was also
produced but was not increased further after stimulation
(Fig 4C). Similarly, we found significant increases in mono-
hydroxy-containing products (Supporting Information Fig S4)
and d5-PD1 production in R-848-treated human monocytes
(Fig 4D). The presence of deuterium in the structure of RvD1 and
PD1 confirmed that TLR7 receptor activation enhanced DHA
utilization and biosynthesis of specialized pro-resolving lipid
mediators by both murine and human cells. Notably, TLR7
but not TLR4 stimulation also up-regulated in macrophages theEMBO Mol Med (2013) 5, 762–775 expression of 5-lipoxygenase and/or 12/15-lipoxygenase
enzymes (Fig 5), rate-limiting components in the metabolism
of DHA to its bioactive derivatives (Hong et al, 2003; Miyata
et al, 2013; Serhan et al, 2006). These data suggest a direct role of
the TLR7 pathway in the generation of SPMs which can be
explained, in part, by its ability to increase the expression of
lipoxygenase enzymes.
Endogenous production of D-series SPMs is critical for TLR7-
mediated resolution of inflammation
To evaluate whether endogenous SPM production is ‘rate-
limiting’ in TLR7-mediated resolution of allergic airway
inflammation, we employed Alox15/ mice. These animals
lack 12/15-lipoxygenase and thus do not convert DHA to its
bioactive components PD1 and RvD1 (Gronert et al, 2005;
Yamada et al, 2011). We found that in these lipoxygenase-
deficient mice the beneficial effects of R-848 treatment were
abrogated. Airway inflammation assessed by determining
inflammatory cell numbers in BALF and leukocytic cell
infiltration did not differ significantly between R-848-treated2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 767
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Figure 5. R-848 up-regulates the expression of 5-lipoxygenase and 12/15-
lipoxygenase enzymes. Mouse macrophages were stimulated for 1 h with
5mg/ml R-848, 1mg/ml LPS or vehicle-treated control (CTL) and analyzed by
real-time PCR.
A. Alox-5 and Alox-15 mRNA levels in peritoneal macrophages expressed as
mean levels SEM relative to GAPDH (n¼6 from two independent
experiments).
B. Alox-5 and Alox-15 mRNA levels in bone marrow-derived macrophages
expressed as mean levels SEM relative to GAPDH (n¼6–10 from two
independent experiments). p<0.05, p<0.01, ns: non-significant
compared to CTL.
768and control mice (Fig 6A–C). Goblet cell metaplasia in the
airways (Fig 6D) and allergen-specific Th2 responses in lung-
draining lymph nodes (Fig 6E) were also not different between
these two groups. These findings suggest that R-848-mediated
pro-resolving activity is directly linked to lipoxygenase-
dependent production of D-series SPMs such as PD1 and
RvD1 in vivo.
Intranasal administration of the D-series SPMs PD1 and RvD1
promotes resolution of established allergic airway
inflammation
Finally, we determined the impact of PD1 or RvD1 treatment to
the resolution of airway inflammation in wild-type mice. We
observed that a single intranasal administration of PD1 or RvD1
given at physiologic range, that is nanograms per mouse, at
day 1 post-challenge effectively accelerated the catabasis of
airway inflammation. Total inflammatory cell and eosinophil
numbers in the BALF were both reduced in PD1 and
RvD1-treated animals compared to vehicle treated controls 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.(Fig 7A and B). Inflammatory cell infiltrates in the lung, goblet
cell metaplasia in the airways and Th2 cell responses in lung-
draining lymph nodes were also similarly reduced (Fig 7C–E).
However, neither synergistic nor additive effects between PD1
and RvD1 were observed. These findings demonstrate that
D-series SPMs such as PD1 and RvD1 exhibit potent pro-
resolving activity in mice with already established allergic
airway inflammation.DISCUSSION
Here we report that TLR7, a receptor recognizing viral ssRNA
and self-RNA released during tissue injury or necrosis,
mobilizes the v-3 DHA-derived biosynthetic pathways leading
to the generation of D-series SPMs. Using targeted lipidomics,
we show that in mouse peritoneal macrophages and human
peripheral blood monocytes, TLR7 drives the production of
DHA-derived monohydroxy metabolites including d5-14-HDHA
and d5-17-HDHA, and the generation of PD1 as well as RvD1.
Using a mouse model of allergic airway inflammation, we
further show that TLR7 enhances the generation of DHA-derived
SPMs including PD1 in vivo. Finally, we demonstrate that TLR7-
mediated induction of DHA-derived SPMs is functionally
important for the catabasis of Th2-mediated inflammation, as
this effect is lost inAlox15/mice, while resolution is enhanced
after local administration of PD1 or RvD1. These findings link
for the first time the activation of TLR7, or any TLR in general,
with the production of resolvins and protectins, and the
resolution of inflammation. They also extend our current view
on the mechanism of action of TLR7 agonists and suggest that
these molecules act at multiple levels to counter-regulate
allergic airway disease. Through the induction of type I IFNs
(Xirakia et al, 2010), they rapidly shut down Th2-mediated pro-
inflammatory responses in the airways. Through the production
of D-series SPMs, they promote resolution of allergic airway
inflammation. Finally, through the generation of regulatory
T cell populations secreting IFN-g (Sel et al, 2007), they ensure
long-term suppression of allergic responses and long-term
remission of allergic airway disease.
Our present results may at first appear paradoxical. TLRs are
major pattern recognition receptors involved in the initiation
and propagation of inflammation, and the ability of TLR7 to
activate a key pro-resolving pathway seems surprising. How-
ever, it is often overlooked that inflammation evolved as
an adaptive response for restoring homeostasis, and that a
successful inflammatory response is always followed by a
resolution and repair phase (Medzhitov, 2008; Serhan et al,
2008). Accordingly, there is evidence that pro-resolving path-
ways are set in motion at the beginning of an inflammatory
response, and become predominant as inflammation enters into
the resolution phase (Serhan et al, 2008). In addition, there are
reports that bacteria or yeast carbohydrates activate PUFA-
derived lipid mediator networks, and although the precise
mechanisms are not known, pattern recognition receptors are
likely involved (Chiang et al, 2012; Kasuga et al, 2008). Finally,
there are studies suggesting that PD1 and RvD1 are also part ofEMBO Mol Med (2013) 5, 762–775
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Figure 6. 12/15-lipoxygenase and production of D-series SPMs are essential for R-848-mediated resolution of allergic airway inflammation.
A. Protocol of R-848 (200mg/mouse) or vehicle (PBS) administration in Alox15/ mice.
B. Total and differential cell counts in BALF of OVA sensitized and challenged (OVA/OVA) mice at day 4 post-challenge. Results are expressed as mean SEM of 8
mice per group.
C. Histological assessment of lung inflammation of Alox15/mice at day 4 post-challenge. Haematoxylin and eosin (H&E)-stained lung sections and histological
scoring expressed as mean values SEM from 8 mice/group are shown.
D. Histological assessment of mucus secretion of Alox15/mice at day 4 post-challenge. Periodic acid Schiff (PAS)-stained sections and morphometric analysis
expressed as mean values SEM from 8 mice/group are shown.
E. Allergen-specific effector T cell responses in mediastinal LNs of Alox15/mice at day 4 post-challenge. Cytokine levels are expressed as mean values SEM in
supernatants of OVA-stimulated mediastinal LN cultures of 8 mice per group. ns: non-significant compared to vehicle-treated control.the antimicrobial defence and enhance bacterial phagocytosis
from macrophages and neutrophils without stimulating uncon-
trolled inflammation and collateral tissue damage (Chiang et al,
2012) or mediating immunosuppression (Norris & Dennis, 2012;
Serhan, 2007; Serhan et al, 2008). Therefore, our findings are
compatible with the known biology of TLRs in innate immunity,
and suggest that induction of SPMs by TLR7 constitutes an
important negative feedback loop that keeps inflammation
under control and ensures its proper resolution.
A question that arises from our study is how DHA-derived
SPMs mediate resolution of Th2-mediated allergic airway
inflammation. Topical (intranasal) treatment of synthetic PD1
or RvD1 given at physiologic range post-allergen challenge
accelerates resolution of established Th2 responses in the
airways, which is in line with prophylactic effects of systemic
PD1 administration on the development of Th2 responses in the
lung previously described (Levy et al, 2007). This could be due
to direct effects on Th2 cell activation and cytokine production,
T cell migration or T cell apoptosis (Ariel et al, 2005).
Alternatively, this could result from indirect effects of PD1EMBO Mol Med (2013) 5, 762–775 on macrophage phagocytic activity and non-inflammatory
apoptotic cell clearance, de-activation of the endothelium,
inhibition of transepithelial migration, or down-regulation of
pro-inflammatory cytokines and enzymes, fostering overall
resolution of inflammation without specifically targeting the
Th2 response (Serhan, 2007; Serhan et al, 2008). In support of
the former possibility, 12/15-lipoxygenase has been shown
to be required for optimal expression of IFN-g in other
experimental settings (Dioszeghy et al, 2008; Middleton et al,
2006; Zhao et al, 2002). Similar mechanisms may also be
employed by RvD1. Although much less is known about its
role in Th2-mediated inflammation, RvD1 has been shown to
inhibit leukotriene-induced secretions from conjunctival goblet
cells (Dartt et al, 2011), suggesting that resolution of goblet
cell metaplasia and mucous hypersecretion during allergic
airway inflammation may be due to direct actions of SPMs in
the lung. Therefore, SPMs such as PD1 and RvD1 stimulate
resolution of inflammation via multi-level mechanisms that
control the catabasis of inflammation and the restoration of
tissue homeostasis.2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 769
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Figure 7. Intranasal administration of PD1 or RvD1 promotes resolution of allergic airway inflammation.
A. Protocol of PD1, RvD1, PD1 and RvD1 (100 ng/mouse) or vehicle (PBS) administration in wild-type mice.
B. Total and differential cell counts in BALF of OVA sensitized and challenged (OVA/OVA) mice at day 4 post-challenge. Results are expressed as mean SEM of 9
mice per group.
C. Histological assessment of lung inflammation at day 4 post-challenge. Haematoxylin and eosin (H&E)-stained lung sections and histological scoring expressed
as mean values SEM from 9 mice/group are shown.
D. Histological assessment of mucus secretion at day 4 post-challenge. Periodic acid Schiff (PAS)-stained sections and morphometric analysis expressed as mean
values SEM from 9 mice/group are shown.
E. Allergen-specific effector T cell responses in mediastinal LNs at day 4 post-challenge. Cytokine levels are expressed as mean values SEM in supernatants
of OVA-stimulated mediastinal LN cultures of 9 mice per group. p< 0.05, p<0.01, p< .001, ns: non-significant compared to vehicle-treated
control.
770Another important question is how TLR7 enhances the
biosynthesis of DHA-derived SPMs. We found that in cultured
peritoneal and bone marrow-derived macrophages TLR7
stimulation up-regulates the expression of 5-lipoxygenase
and/or 12/15-lipoxygenase enzymes, rate-limiting components
in the metabolism of DHA to its bioactive derivatives (Hong 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.et al, 2003; Miyata et al, 2013; Serhan et al, 2006). Notably, 12/
15-lipoxygenase expression has been shown to mark alterna-
tively activated macrophages and to play a key role in the
clearance of apoptotic cells and the maintenance of tissue
homeostasis (Uderhardt et al, 2012), raising the possibility that
TLR7 stimulation, alternatively activated macrophage functionEMBO Mol Med (2013) 5, 762–775
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mediated regulation of lipoxygenases may not be the only
mechanism involved as substrate availability is also critical.
in vivo, regulation of substrate availability is complex and
involves multiple sources including lung resident cells and
infiltrating leukocytes that carry esterified DHA in membrane
phospholipids (such as phosphatidylethanolamine and phos-
phatidylcholine), and oedema which provides unesterified DHA
to local sites of inflammation (Hong et al, 2003; Kasuga et al,
2008; Marcheselli et al, 2003; Serhan, 2010). It is therefore
possible that TLR7 enhances the biosynthesis of D-series SPMs
by also affecting substrate availability as it has been previously
shown that R-848 canmobilize eicosanoids from esterified lipids
and increase oedema formation (Hattermann et al, 2007; Norris
& Dennis, 2012; Takeuchi & Akira, 2010).
Other SPMs have also been studied in asthma. Resolvin E1
(RvE1) exhibits potent pro-resolving activity in allergic airway
inflammation by inhibiting Th17 without affecting Th2
responses in the airways while increasing IFN-g (Haworth et
al, 2008). Lipoxin A4, biosynthesized from arachidonic acid
following lipid mediator class switching, is another pivotal
SPM. LXA4 is present in sputum and BALF of severe asthmatic
patients (Levy et al, 2005; Planaguma et al, 2008) and has been
identified in BALF of BALB/c mice with allergic airway
inflammation (Haworth et al, 2008). Unfortunately, we have
not examined BALF in our setting in C57BL/6 mice while we
have not been able to detect LXA4 above the limit of
quantification in lung tissue. LXA4 prevents the development
of Th2 responses and Th2-mediated inflammation in the lung
although its pro-resolving potential has not been sufficiently
investigated (Levy et al, 2002). Hence, the description in our
study of an endogenous mechanism that drives the catabasis of
acute allergic airway inflammation, and the identification of
a pharmaceutical agonist that can accelerate this process,
constitute important steps forward towards understanding
resolution in asthma.
A surprising observation in our studies was that Tlr7/mice
exhibited significantly delayed resolution of inflammation. This
pointed to the presence of endogenous TLR7 ligand(s) and
suggested that TLR7 is part of an endogenous regulatory
mechanism that acts to keep inflammation under control and
restore tissue homeostasis. In an effort to identify potential TLR7
ligands, we tested for the presence of extracellular RNA in
inflamed lung using an established protocol (Ganguly et al,
2009; Salagianni et al, 2012) and found that RNA aggregates –
presumably released from damaged cells – are detectable in
acellular areas of the inflamed tissue (Supporting Information
Fig S5). These are likely to constitute endogenous ligands for
TLR7 and contribute to TLR7-mediated signalling in vivo.
Further studies will be needed to define the exact nature and
immunostimulatory potential of these structures as well as their
cellular targets as multiple immune (alveolar macrophages,
myeloid and plasmacytoid dendritic cells, eosinophils) and
structural cells (bronchial epithelial cells) in the lung expressing
abundant levels of TLR7 (Bessa et al, 2009; Cherfils-Vicini et al,
2010; Demedts et al, 2006; Maris et al, 2006; Nagase et al, 2003;
Xirakia et al, 2010). Our present results have direct therapeuticEMBO Mol Med (2013) 5, 762–775 implications for the treatment of aberrant inflammatory
responses during acute exacerbations of asthma. Traditional
approaches involve the administration of inhaled or systemic
corticosteroids, often in combination with anti-leukotriene
inhibitors, but their therapeutic efficacy is limited, especially
in the most severe cases of the disease (Jackson et al, 2011).
Rather than inhibiting molecular events that occur at the
beginning of the immune response, a process that may thwart
the body’s own attempt to heal, our study now proposes a new
approach for taming inflammation by directly stimulating
endogenous resolution mechanisms; the induction of SPMs
via the activation of the TLR7 pathway. TLR7 activation may be
particularly suited for the treatment of acute exacerbations of
asthma as these are often due to viral infections, and in addition
to its potent pro-resolving function, TLR7 also exhibits strong
antiviral activity (Blasius & Beutler, 2010; O’Neill & Bowie,
2010). As several TLR7 or TLR7/8 agonists are under clinical
development for the treatment of various diseases including
respiratory allergies (Hennessy et al, 2010; Kanzler et al, 2007),
their efficacy in clinical trials of allergic asthma exacerbations
are eagerly awaited.
In summary, our results reveal a new previously unantici-
pated role of TLR7 in the production of DHA-derived SPMs and
the catabasis of Th2-mediated inflammation. They demonstrate
that a TLR, and a selective TLR agonist, drive the production of
SPMs and actively mediate resolution of inflammation. They
also suggest the existence of a negative feedback loop triggered
by TLR7 that counter-regulates inflammation and ensures its
proper resolution and catabasis. This broadens our current view
of TLR function in health and disease, and has profound
implications for the development of TLR agonists and
antagonists in the clinic. Moreover, our study unravels a new
mode of action of resiquimod, an existing antiviral drug of the
imidazoquinoline family, and establishes TLR7/8 agonists as
the first pharmacological agents beyond aspirin and statins that
are capable of directly inducing the lipoxygenase-dependent
biosynthetic pathways leading to the production of SPMs.
This strengthens the rationale for the application of TLR7/8
agonists for the treatment of allergic asthma and respiratory
allergies in general, and supports their development for
other diseases driven by non-resolving inflammation. Unwind-
ing the complex molecular machinery controlling SPM
production, and dissecting the pro-resolving from the pro-
inflammatory pathways triggered by TLR7 may therefore
provide a key to the future treatment of a wide range of chronic
and devastating diseases by stimulating endogenous resolution
mechanisms.MATERIALS AND METHODS
Mice
Wild type and Alox15/ mice on a C57BL/6J background were
purchased from Jackson Laboratories (USA). Toll-like receptor-7-
deficient (Tlr7/) mice (Hemmi et al, 2002) were obtained
from Prof. S. Akira (Osaka University, Japan) and backcrossed to the
C57BL/6J background for at least 10 generations. Mice were fed2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 771
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772a normal chow diet containing 18.5% protein and 5.5% fat
(Harlan Tekland, Italy) and housed in individually ventilated cages
(IVC) under specific pathogen-free conditions in full compliance to
FELASA recommendations at the Animal House Facility of the
Foundation for Biomedical Research of the Academy of Athens. All
procedures had received prior approval from the Institutions and
Regional Ethical Review Boards and were in accordance with the US
National Institutes of Health Statement of Compliance (Assurance)
with Standards for Humane Care and Use of Laboratory Animals
(#A5736–01) and with the European Union Directive 86/609/EEC for
animal research.
Experimental protocols and treatments
An established model of allergic airway disease in mice was used
(Koltsida et al, 2011; Xirakia et al, 2010). Briefly, 6- to 8-week-old mice
were sensitized with two intraperitoneal injections of OVA (Grade V;
Sigma) complexed with aluminium hydroxide (alum) and subse-
quently challenged for 3 consecutive days with aerosolized 5% w/v
OVA in PBS (OVA/OVA) for 30min per day. Control mice received
intraperitoneal injections and challenges of PBS (PBS/PBS) or
intraperitoneal injections of OVA and challenges of PBS (OVA/PBS).
Mice were treated with 200mg/mouse resiquimod (R-848) or
100ng/mouse PD1 and/or RvD1 at day 1 post-allergen challenge as
indicated in the experimental protocol. At indicated timepoints,
mice were examined for the development of allergic airway
inflammation by performing bronchoalveolar lavage, differential cell
counting, histological scoring and lymph node T cell assays as detailed
below.
Bronchoalveolar lavage and differential cell counts
BALF of the whole lung was performed twice with 0.5ml saline. Cells
were counted and cell pellets subjected to cytospin centrifugation at
600 rpm for 3min. Cytospins were stained with May-Grunwald-
Giemsa and analyzed by differential cell counting. At all cases,
<5102 eosinophils or neutrophils were detectable in BALF from
PBS/PBS or OVA/PBS control mice.
Histological analysis
Lung tissue was fixed in 10% v/v neutral buffered formalin and
embedded in paraffin. Paraffin-embedded tissue slices were stained
with haematoxylin/eosin (H&E) or periodic acid Schiff’s (PAS) solution
(Sigma, Deisenhofen, Germany). Histopathologic analysis of inflam-
matory cells in H&E stained lung sections from at least six mice was
performed in a blinded fashion using a semi-quantitative scoring
system as previously described (Koltsida et al, 2011; Xirakia et al,
2010). Both peribronchial and perivascular inflammation were scored
giving a maximum score of 8 as follows: 0, normal; 1, few cells; 2, a
ring of inflammatory cells one cell layer deep; 3, a ring of
inflammatory cells two to four cells deep; and 4, a ring of
inflammatory cells of more than four cells deep. Histological
score for PBS/PBS control mouse lungs was always 0. Morphometric
analysis of PAS stained sections was performed by quantifying
PAS pixels per mm length distance of bronchial epithelium of
central airways using the Image J software. At least six areas
from similar sections per mouse and at least six mice were
assessed blindly. PAS score for PBS/PBS control mouse lungs was
constantly <2. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Lymph node cultures
Mediastinal lymph nodes were removed, single cell suspensions
prepared and cells cultured at 5105/well in 96-well plates in the
presence or absence of 100mg/ml ovalbumin. After 48 h, supernatants
were collected and examined by ELISA for the presence of Th1, Th2
and Th17 cytokines. Background levels of cytokine production from
PBS/PBS mice were always <20pg/ml for IL-5, IL-10, IL-13, IL-17
and IFN-g. DuoSetTM sandwich ELISA kits were from eBioscience
(California, USA).
Airway hyperresponsiveness
Airway hyperresponsiveness was measured in anaesthetized mechanically
ventilated mice (flexiVent, SciReq, Montreal, Canada) 24 or 96h after the
last aerosol exposure as previously described (Xirakia et al, 2010).
Mouse resident macrophage incubations and lipid mediator
lipidomics
Peritoneal lavages from 6- to 8-week-old FVB male mice (Charles River
Laboratories, Willington, USA) fed with Lab Diet 5001 were harvested,
cells left to adhere in 6-well plates and then incubated with 100mM
R-848 (Invivogen, CA, USA), 100mg/ml Zymosan A (Sigma, MO, USA) or
vehicle control (PBS) in the presence of 10mM d5-DHA (Cayman
Chemicals, MI, USA) for 1 h at 378C. The incubations were stopped
using ice-cold methanol and addition of deuterium-labelled standards
(d8-5-HETE, d4-PGE2 and d4-LTB4), and cells/supernatants were
collected and kept in 808C till evaluation. Lipid mediators from these
samples were extracted using C-18 solid phase extraction (SPE) and
then analyzed using LC-MS–MS. LC-MS-MS-based mediator lipidomics
was conducted using linear ion trap quadrupole mass spectrometer
(3200 QTRAP, Applied Biosystems, Foster City, CA) equipped with two
HPLC pumps (LC20AD, Shimadzu, Columbia, MD) coupled to a reverse
phase column (Eclipse Plus C18, 50mm4.6mm1.8mm, Agilent
Technologies Inc., Santa Clara, CA). The mobile phase consisted
of methanol:water:acetic acid 60:40:0.01 v/v/v with flow rate at
0.4ml/min; the mobile phase was gradually increased to 100:0:0.01
over 12min and kept at 100:0:0.1 for 2min. All lipid mediators were
identified according to published criteria including matching retention
times and at least 4–6 prominent diagnostic ions present in their
MS/MS spectra (Yang et al, 2011).
Human monocytes cultures and lipid mediator lipidomics
Peripheral blood mononuclear cells were isolated by dextran-
Histopaque (1.077 g/ml) double gradient from whole blood from
healthy volunteers (de-identified) who denied taking medications
2 weeks before donation (Partners Human Research Committee
Protocol no. 88-02642). Informed consent was obtained from all
donors. Peripheral blood monocytes were purified by adherence
following plating of PBMCs into 6-well plates (10106/well) and
incubation for 1 h at 378C. Cells were subsequently washed twice with
PBS, left to rest for 5 h in RPMI containing 10% FBS, L-glutamine and
penicillin/streptomycin, and stimulated for 1 h at 378C with 100mM
R-848 (Invivogen, CA, USA), 100mg/ml Zymosan A (Sigma, MO, USA),
100mM R-848 and 100mg/ml Zymosan A, or vehicle control (PBS) in
the presence of 10mM d5-DHA (Cayman Chemicals, MI, USA). The
experiment was stopped using ice-cold methanol and addition
of deuterium-labelled internal standards (d8-5-HETE, d4-PGE2 and
d4-LTB4), and samples processed as above.EMBO Mol Med (2013) 5, 762–775
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The paper explained
PROBLEM:
The production of oxygenated lipids derived from polyunsatu-
rated fatty acids, altogether termed specialized proresolving lipid
mediators (SPMs), is critical for the resolution of inflammation.
Defects or delays in their production result in delayed resolution,
prolonged inflammation and increased tissue damage. Still, the
mechanisms and pathways that can drive their production,
especially in the context of inflammatory disease, remain elusive,
thus hampering the rational design of novel therapeutics aiming
at actively resolving inflammation.
RESULTS:
We report that TLR7, a major pattern recognition receptor
recognizing viral single stranded RNA and damaged self-RNA,
drives the biosynthesis of docosahexaenoic acid (DHA)-derived
SPMs (termed D-series SPMs) and the resolution of airway
inflammation. Using mouse peritoneal macrophages, human
peripheral blood monocytes and a murine model of allergic
airway inflammation, we demonstrate that TLR7 triggers the
production of DHA-derived monohydroxy metabolome markers
(d5-7-HDHA, d5-14-HDHA and d5-17-HDHA), the generation of
protectin D1 (PD1) and resolvin D1 (RvD1), and the catabasis of
Th2-mediated inflammation. We further show that the pro-
duction of D-series SPMs is key to TLR7 proresolving function,
while intranasal administration of synthetic PD1 or RvD1 can be
used therapeutically to drive resolution of allergic airway
inflammation.
IMPACT:
Our study uncovers a previously unsuspected mechanism that
links innate immunitywith the resolution of inflammation. It also
reveals a new molecular pathway triggered by TLR7 that drives
the production of omega-3 polyunsaturated fatty acid-derived
SPMs such as PD1 and RvD1, and suggests that it is possible
to harness TLR function to promote resolution of airway
inflammation. This broadens our current view of TLR function in
health and disease, and has profound implications for the
development of novel therapeutics aiming at actively
resolving inflammation. In addition, our study proposes a new
mode of action of resiquimod, an existing antiviral drug of
the imidazoquinoline family, and establishes TLR7 agonists
as the first pharmacological agents beyond aspirin and
statins that directly induce the lipoxygenase-dependent
biosynthetic pathway leading to the production of SPMs.
Finally, our study supports the application of TLR7 agonists
for the treatment of allergic asthma and respiratory
allergies in general, especially during exacerbations, and their
development for other diseases driven by non-resolving
inflammation.Lipid mediator-lipidomics with lung samples
Frozen lung samples were placed into methanol, and organ samples
dispersed in cold methanol using a Kontes tissue grinder to gently
elute lipid mediators from the tissue, and after addition of internal
standard for specific lipid mediators (as above), were taken for
extractions using C18 solid phase extraction (SPE). Samples were
taken for analysis using LC-MS–MS and published criteria including
matching retention times and at least 4–6 prominent diagnostic ions
present in their MS/MS spectra (Yang et al, 2011).
Macrophage cultures and quantitative real-time PCR
Peritoneal and bone marrow-derived macrophages were cultured in
DMEM containing 10% foetal calf serum, 100U/ml penicillin,
100mg/ml streptomycin and 2mM L-glutamine 1% penicillin/streptomycin.
For bone marrow-derived macrophages, the medium was also
supplemented with 20% L929 supernatant as previously described
(Harding, 2001). Peritoneal macrophages were stimulated for 1h with
5mg/ml R-848 (Invivogen, CA, USA) or 1mg/ml LPS (Sigma, MO, USA)
and collected for further analysis. Similarly, bone marrow macro-
phages were stimulated for 1 h with 5mg/ml R-848 or 10 ng/ml LPS
(Sigma, MO, USA). Total RNA was isolated using the TRIZOL Reagent
(Sigma, MO, USA) and cDNA was generated by RT-PCR using the
M-MLV reverse transcriptase according to the manufacturer’s instruc-
tions (Promega, USA). Real-time quantitative PCR was performed with
the SYBR1 Green ERTM qPCRSuperMix Universal (Invitrogen, UK).EMBO Mol Med (2013) 5, 762–775 Target mRNA levels were expressed relative to GAPDH. Primer sets
used were the following: GAPDH sense 50-CCAGTATGACTCCACTCACG-
30 , GAPDH antisense 50-CTCCTGGAAGATGGTGATGG-3’, Alox5 sense 50-
ACATCCTCAAGCAGCACAGAC-30 , Alox5 antisense 50-GCATCAATACT-
CAAAGGGAAGCC-30 , Alox15 sense 50-CTGCCCGCCTGGTATTCC-30 ,
Alox15 antisense 50-AATCCGCTTCAAACAGAGTGC-30 .
Statistical Analysis
Statistical significance of differences was assessed by Student t-test
for parametric data and by Mann–Whitney U (MWW) test for non-
parametric data. Differences were considered significant when p<0.05.Author contributions
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